

## Datasheet: MCA2113PET

<b>Description:</b>	MOUSE ANTI HUMAN CD46:RPE
<b>Specificity:</b>	CD46
<b>Other names:</b>	MEMBRANE CO-FACTOR PROTEIN
<b>Format:</b>	RPE
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	MEM-258
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	25 TESTS/0.25ml

### Product Details

#### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	▪			Neat

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

<b>Target Species</b>	Human		
<b>Product Form</b>	Purified IgG conjugated to R. Phycoerythrin (RPE) - lyophilized		
<b>Reconstitution</b>	Reconstitute with 0.25 ml distilled water		
<b>Max Ex/Em</b>	<b>Fluorophore</b>	<b>Excitation Max (nm)</b>	<b>Emission Max (nm)</b>
	RPE 488nm laser	496	578
<b>Preparation</b>	Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant		
<b>Buffer Solution</b>	Phosphate buffered saline		
<b>Preservative</b>	0.09% sodium azide (NaN <sub>3</sub> )		
<b>Stabilisers</b>	1% bovine serum albumin		
	5% sucrose		

Immunogen HPB-ALL cell line.

---

**External Database**

**Links**

**UniProt:**

[P15529](#)    [Related reagents](#)

**Entrez Gene:**

[4179](#)    CD46    [Related reagents](#)

---

**Synonyms**

MCP, MIC10

---

**RRID**

AB\_1102096

---

**Specificity**

**Mouse anti Human CD46 antibody, clone MEM-258** recognizes the human CD46 cell surface antigen, also known as membrane co-factor protein (MCP), Trophoblast leukocyte common antigen or TLX. CD46 is a 392 amino acid (including a 34 aa signal peptide) ~43-60 kDa single pass type 1 transmembrane glycoprotein expressed by all cell types with the exception of erythrocytes.

CD46 functions as a receptor for complement and inhibitor of complement activation, limiting the formation and activity of C3 convertases. CD46 is expressed by all nucleated cells, often as multiple isoforms (Seya *et al.* 1993) on the same cells. The molecule is also expressed by sperm and may be important in the process of fertilisation (Carver-Ward *et al.* 1996).

---

**Flow Cytometry**

Use 10µl of the suggested working dilution to label 10<sup>6</sup> or 100µl whole blood

---

**References**

1. Sirena D *et al.* (2004) The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. [J Virol. 78 \(9\): 4454-62.](#)
2. Fremieux-Bacchi, V. *et al.* (2006) Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. [J Am Soc Nephrol. 17 \(7\): 2017-25.](#)
3. Fleischli, C. *et al.* (2005) The distal short consensus repeats 1 and 2 of the membrane cofactor protein CD46 and their distance from the cell membrane determine productive entry of species B adenovirus serotype 35. [J Virol. 79:10013-22.](#)
4. Sweigard, J.H. *et al.* (2010) Adenovirus vectors targeting distinct cell types in the retina. [Invest Ophthalmol Vis Sci. 51:2219-28.](#)
5. Yang, P. *et al.* (2009) Expression and modulation of RPE cell membrane complement regulatory proteins. [Invest Ophthalmol Vis Sci. 50: 3473-81.](#)
6. Bahat, A. and Eisenbach, M. (2010) Human sperm chemotaxis is mediated by phospholipase C and inositol trisphosphate receptor Ca<sup>2+</sup> channel. [Biol Reprod. 82: 606-16.](#)
7. Bienaime, F. *et al.* (2010) Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. [Kidney Int. 77: 339-49.](#)
8. Wang, H. *et al.* (2008) *In vitro* and *in vivo* properties of adenovirus vectors with increased affinity to CD46. [J Virol. 82: 10567-79.](#)
9. Hara, H. *et al.* (2011) Initial *in vitro* investigation of the human immune response to

- corneal cells from genetically engineered pigs. [Invest Ophthalmol Vis Sci. 52: 5278-86.](#)
10. El Karoui, K. *et al.* (2012) A clinicopathologic study of thrombotic microangiopathy in IgA nephropathy. [J Am Soc Nephrol. 23 \(1\): 137-48.](#)
11. Bach, P. *et al.* (2013) Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. [Cancer Res. 73 \(2\): 865-74.](#)
12. Leaderer, D. *et al.* (2015) Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59. [J Gene Med. 17 \(6-7\): 101-15.](#)
13. Tuve, S. *et al.* (2006) A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. [J Virol. 80 \(24\): 12109-20.](#)
14. Hara, H. *et al.* (2008) *In vitro* investigation of pig cells for resistance to human antibody-mediated rejection. [Transpl Int. 21 \(12\): 1163-74.](#)
15. Loré, K. *et al.* (2007) Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. [J Immunol. 179 \(3\): 1721-9.](#)
16. Fremeaux-Bacchi, V. *et al.* (2007) Unusual clinical severity of complement membrane cofactor protein-associated hemolytic-uremic syndrome and uniparental isodisomy. [Am J Kidney Dis. 49 \(2\): 323-9.](#)
17. Le Quintrec, M. *et al.* (2008) Complement mutation-associated *de novo* thrombotic microangiopathy following kidney transplantation. [Am J Transplant. 8 \(8\): 1694-701.](#)
18. Boyer, O. *et al.* (2008) Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. [Am J Kidney Dis. 51 \(4\): 671-7.](#)
19. Wang, H. *et al.* (2009) Receptor usage of a newly emergent adenovirus type 14. [Virology. 387 \(2\): 436-41.](#)
20. Iguchi, K. *et al.* (2012) Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells. [Cancer Gene Ther. 19 \(2\): 118-25.](#)
21. Kälin, S. *et al.* (2010) Macropinocytotic uptake and infection of human epithelial cells with species B2 adenovirus type 35. [J Virol. 84 \(10\): 5336-50.](#)
22. Bottino, R. *et al.* (2014) Pig-to-monkey islet xenotransplantation using multi-transgenic pigs. [Am J Transplant. 14 \(10\): 2275-87.](#)
23. White, K.M. *et al.* (2013) Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile. [J Cardiothorac Surg. 8: 183.](#)
24. Tuve, S. *et al.* (2008) Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35. [PLoS Pathog. 4 \(10\): e1000189.](#)
25. Iwase, H. *et al.* (2014) Regulation of human platelet aggregation by genetically modified pig endothelial cells and thrombin inhibition. [Xenotransplantation. 21 \(1\): 72-83.](#)
26. Sweigard, J.H. *et al.* (2011) Adenovirus-mediated delivery of CD46 attenuates the alternative complement pathway on RPE: implications for age-related macular degeneration. [Gene Ther. 18 \(6\): 613-21.](#)

---

**Storage**

Prior to reconstitution store at +4°C.

After reconstitution store at +4°C.

DO NOT FREEZE.

This product should be stored undiluted. This product is photosensitive and should be protected from light. Should this product contain a precipitate we recommend microcentrifugation before use.

---

**Guarantee** 12 months from date of despatch

---

**Health And Safety Information** Material Safety Datasheet documentation #20487 available at:  
<https://www.bio-rad-antibodies.com/SDS/MCA2113PET>  
20487

---

**Regulatory** For research purposes only

---

## Related Products

### Recommended Negative Controls

[MOUSE IgG1 NEGATIVE CONTROL:RPE \(MCA928PE\)](#)

### Recommended Useful Reagents

[HUMAN SEROBLOCK \(BUF070A\)](#)

[HUMAN SEROBLOCK \(BUF070B\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)  
'M412900:221117'

**Printed on 28 Apr 2023**

---

© 2023 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)